Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05544019 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of SGR-1505 in Mature B-Cell Neoplasms

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 52 to 98
    • Primary and study completion dates: Mar 2026 to Nov 2027
    v19
  2. Re-verified, no change to tracked fieldsv18
  3. Study sites: 17 to 36v17
  4. Re-verified, no change to tracked fieldsv16
  5. Study sites: 16 to 17v15
Show 13 earlier versionsHide 13 earlier versions
  1. Study sites: 15 to 16v14
  2. Primary and study completion dates: Mar 2025 to Mar 2026v13 Show 4 more changesShow less
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoints: 12 to 6
    • Study description shortened, about 6 words
    • Study arms: 2 to 1
  3. Study sites: 14 to 15v12
  4. Study sites: 13 to 14v11
  5. Study sites: 8 to 13v10
  6. Study sites: 7 to 8v9
  7. Study sites: 5 to 7v8
  8. Study sites: 4 to 5v7
  9. Study sites: 3 to 4v6
  10. Study description expanded, about 5 wordsv5
  11. Primary and study completion dates: Mar 2024 to Mar 2025
    • Start date changed from estimate of Jun 2023 to Apr 10, 2023
    v4
  12. Start date: Oct 2022 to Jun 2023
    • Study sites: 1 to 3
    v3
  13. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Sep 2022 to Oct 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Schrödinger, Inc.
2 trials monitored
See all monitored trials
Leukemia
2,948 trials monitored
See 180 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
DLBCL
703 trials monitored
See 44 trials at risk
and 3 more diseases
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Trial Details
NCT Number NCT05544019
Lead Sponsor Schrödinger, Inc.
Conditions
(from sponsor)		 Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement +18 more
Related terms Burkitt Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Primary Effusion, Plasmablastic Lymphoma, Pyloric Stenosis, Hypertrophic, Waldenstrom Macroglobulinemia
Enrollment 98 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov